Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €28.78 EUR
Change Today -0.22 / -0.76%
Volume 150.0
As of 3:54 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

sarepta therapeutics inc (AB3A) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/21/15 - €31.48
52 Week Low
01/14/15 - €9.62
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

sarepta therapeutics inc (AB3A) Details

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin. The company also focuses on developing therapeutics for the treatment of drug-resistant bacteria, Becker muscular dystrophy, progeria, adult onset pompe, lupus and graft-versus-host diseases; and other rare, genetic, anti-infective, neuromuscular, and central nervous system diseases. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

204 Employees
Last Reported Date: 02/26/15
Founded in 1980

sarepta therapeutics inc (AB3A) Top Compensated Officers

Interim Chief Executive Officer, Chief Medica...
Total Annual Compensation: $399.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $443.7K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $393.4K
Senior Vice President of Technical Operations
Total Annual Compensation: $335.9K
Compensation as of Fiscal Year 2014.

sarepta therapeutics inc (AB3A) Key Developments

Sarepta Therapeutics Appoints Henri Termeer as Advisor to the Company

Sarepta Therapeutics, Inc. announced Henri Termeer, industry leader and former CEO of Genzyme, will be a key advisor to the Company. Henri Termeer is the former chairman, president and chief executive officer of Genzyme Corporation, where he served for nearly three decades until retiring in 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion.

Sarepta Therapeutics, Inc. Secures $40 Million in Debt Financing

Sarepta Therapeutics, Inc. announced that it entered into a credit and security agreement with Midcap Financial that establishes a senior secured term loan facility that allows Sarepta to borrow up to $40,000,000 at an annual rate of 7.75%, with a maturity of June 2018, subject to certain conditions and other applicable fees. Sarepta has drawn down $20,000,000 under the facility and has the right to repay all borrowed funds and terminate the facility at any time.

Sarepta Therapeutics Completes NDA Submission to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Sarepta Therapeutics, Inc. announced the completion of the rolling submission of a New Drug Application to the United States Food and Drug Administration for eteplirsen on June 26, 2015. Eteplirsen, the company's lead drug candidate, targets the underlying cause of Duchenne muscular dystrophy and is designed to enable the production of a functional internally truncated dystrophin protein in patients with mutations amenable to exon 51 skipping. Approximately 13% of people with Duchenne muscular dystrophy are estimated to have a mutation targeted by Eteplirsen/exon 51 skipping. The NDA submission includes a request for Priority Review. Previously, eteplirsen has been granted Orphan and Fast Track status by the FDA. The rolling submission of the NDA began on May 20, 2015, after the completion of a pre-NDA meeting with the FDA held on May 19, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AB3A:GR €28.78 EUR -0.22

AB3A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$0.92 AUD +0.03
Galena Biopharma Inc $1.64 USD -0.02
Regulus Therapeutics Inc $8.20 USD -0.06
Silence Therapeutics PLC 278.00 GBp -2.37
View Industry Companies

Industry Analysis


Industry Average

Valuation AB3A Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 359.5x
Price/Book 6.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 313.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at